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Abstract: Human mesenchymal stem cells (hMSCs) have been widely studied for therapeutic
development in tissue engineering and regenerative medicine. They can be harvested from human
donors via tissue biopsies, such as bone marrow aspiration, and cultured to reach clinically relevant
cell numbers. However, an unmet issue lies in the fact that the hMSC donors for regenerative
therapies are more likely to be of advanced age. Their stem cells are not as potent compared to
those of young donors, and continue to lose healthy, stemness-related activities when the hMSCs are
serially passaged in tissue culture plates. Here, we have developed a cheap, scalable, and effective
copolymer film to culture hMSCs obtained from aged human donors over several passages without
loss of reactive oxygen species (ROS) handling or differentiation capacity. Assays of cell morphology,
reactive oxygen species load, and differentiation potential demonstrate the effectiveness of copolymer
culture on reduction in senescence-related activities of aging donor-derived hMSCs that could hinder
the therapeutic potential of autologous stem cell therapies.
Keywords: biomaterial; copolymer; stem cell; regenerative medicine; cell culture
1. Introduction
Human mesenchymal stem cells (hMSCs) offer a potential stem cell source for the translation of
tissue engineering strategies to repair or replace damaged tissues. In fact, several proof-of-principle
studies of direct stem cell injections into injury sites have resulted in improved function, such as in
bone [1], cartilage [2], heart [3], and large blood vessels [4]. However, to effectively translate these
studies to human clinical trials, hundreds of millions of hMSCs need to be grown for transplantation
at the injury site to be effective, as has been demonstrated in large animal studies [5]. Thus, a few
hundred thousand hMSCs that can be isolated from the bone marrow of any typical human donor
require expansion and break the Hayflick limit in the process [6]. Originally described in 1961,
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Leonard Hayflick and his colleagues observed that cells had decreased proliferation as they were
serially passaged in Petri dishes. This could become an obstacle to translating hMSCs for therapeutic
applications, because donors who would most often utilize such stem cell therapies are of advanced
age, and their hMSCs have likely undergone the process of senescence due to the many cycles of cell
division occurring over the donor’s lifetime.
hMSC phenotype undergoes senescence-associated changes from serial passaging on tissue
culture polystyrene (TCPS) due to cytotoxic insults such as the accumulation of the intracellular
reactive oxygen species (ROS) [7]. Seminal work by Wagner and colleagues reported that excessive
passaging of hMSCs resulted in a host of biochemical and functional alterations that were detrimental
to cell health [8]. Among their findings, surface markers unique to hMSCs diminished or disappeared,
coupled with profound alterations in mRNA expression profiles indicative of spontaneous differentiation,
apoptosis, cell cycle alterations, and inflammatory regulation. Cell proliferation also arrested and was
coupled to decreased differentiation capacity and increased β-galactosidase staining (a well-established
positive marker of cellular senescence). These observations were further verified in hematopoietic
stem cell progenitors by the same research group in order to demonstrate that senescence-associated
changes incurred in vitro were limited to hMSCs [9].
Similarly, Heo et al. conducted serially passaging studies on hMSCs that not only confirmed the
original findings by Wagner et al., but also specifically reported the loss of ROS handing proteins as the
upstream event that leads to hMSC senescence in vitro [7]. Reduced expression of APE/Ref-1 due to
serial passaging yielded increased ROS loads within hMSCs, which in turn accelerated accumulation of
β-galactosidase. These effects could be countered if APE/Ref-1 was overexpressed, and thus restored
homeostatic ROS levels. Kasper and colleagues further explored this phenomenon by looking at
proteomic alterations in young and old rat MSCs [10]. Older rats had fewer MSCs in the bone marrow
with concordant susceptibility in cellular senescence due to their inability to process ROS. Proteomic
profiling validated that the overabundance of ROS resulting in extensive macromolecular damage
could not be overcome with hindered antioxidant mechanisms caused by cellular senescence.
Aged hMSCs exhibit altered differentiation potential: younger cells are able to maintain multipotency
(e.g., osteogenic, adipogenic, chondrogenic differentiation capacity), but over multiple passages, older
cells are only able to differentiate into osteogenic and adipogenic lineages, and eventually only the
osteogenic lineage [11]. We have also reported that serially passaged hMSCs are more susceptible
to cancerous transformation, and the probability and degree of cancerous transformation is closely
correlated with β-galactosidase staining [12]. This becomes especially concerning for aged donors
whose cells have already undergone many divisions and could have hMSCs that harbor ROS-mediated
DNA damage that can more easily yield cancerous stem cells.
In order to expedite clinical translation, new, cheap, easily scalable strategies to maintain or
reinstate hMSC fitness following expansion must be developed to counteract this inherent decline in
cell health [13]. Generation of spheroid aggregates of hMSCs has been considered one of the most
effective cultural formats for maintaining hMSC therapeutic potency and avoiding passage-associated
senescence [14,15]. In fact, hMSC cell aggregates benefit from having increased functional capacity
such as pro-angiogenic [16] and anti-inflammatory properties [15,17–19]. However, generating large
quantities of aggregates from bioreactors or cell-repellant substrates can result in varying degrees
of success, as evidenced in the literature. Maintaining bioreactor systems has the complexity of
interconnected bioreactor components and unique contamination risks (e.g., chemical or biological)
that complicate the scaling up of this process [20]. Several groups have noted that optimization of
bioreactor yields requires improvement despite the careful monitoring of growth conditions [21], and
that precursor hMSC populations from the original in vivo aspirate are modified and/or lost after
20 population doublings [22]. Additionally, controlling the size of the hMSC aggregates during a
scale-up of the bioreactor risks the aggregates developing necrotic cores that could result in negative
consequences for the recipient tissues receiving the cells [23–25]. Moreover, the ability to handle and
break down these aggregates into single cell suspensions for injection is difficult.
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Approaches other than aggregates have also been developed for the extensive culture of hMSCs.
With respect to culture substrates, many groups have employed inverted hanging drop wells that
have cell-repellant surfaces [15,26–28]. In one study by Ng et al., adipose MSCs were expanded
in vitro by culturing on extracellular matrix (ECM) protein produced by fetal MSCs [29]. Although the
adipose MSCs demonstrated increased functional capacity over several passages, concerns regarding
immunogenicity arise when using ECM from another human donor, which could ultimately stimulate
a negative immune response by the stem cell recipient. Also, the financial burden of continually
generating uniform fetal ECM and harvesting fetal MSCs to generate the ECM could become
exponential. Alternatively, other groups like Duffy et al. have developed synthetic polymer culture
substrates that reduce harsh passaging techniques to grow hMSCs over many passages [30]. While
their enzyme-free substrate did demonstrate marginal improvement in adipose MSC differentiation,
the surface marker profiles were not maintained, thereby challenging the efficacy of the system beyond
simple differentiation assays and the monolayer appearance of the cells.
Using these studies as inspiration, we set out to demonstrate a cheap, easily-reproducible, and
effective culture platform that could maintain stem cell phenotype and functional capacity over
serial passaging. In previous work, we found that by using a poly(ethylene glycol) (PEG) and
poly(ε-caprolactone) (PCL) copolymer film as a culture substrate, human bone marrow-derived
MSCs maintained high stemness, retained key surface protein markers lost during in vitro culture
(STRO-1), contained low reactive oxygen species load, and adopted decreased proliferation rates
compared to conventional TCPS plates [31]. Morphologically, the moderate repellency of specific
PEG-PCL (poly(ethylene glycol)-poly(ε-caprolactone)) film compositions created an optimal interface
that allowed hMSCs to bind the amorphous PCL domains while the hydrophilic PEG domains forced
the cells to aggregate into spheroids that were morphologically similar to marginating hMSCs in the
bone marrow. Therefore, because we had validated that our PEG-PCL copolymers could reproduced in
the aforementioned findings in random hMSC donors, we hypothesized that the PEG-PCL copolymer
films could be used to serially-passage hMSCs from aging donors (age > 65 years old) as a means to
attenuate senescence-associated activities resulting from serial in vitro expansion. We demonstrate that
culture on this material maintains the cells in a pro-stemness state throughout expansion, as evidenced
by a series of functional assays including flow cytometry detection of reactive oxygen species (ROS),
and adipogenic and osteogenic differentiation assays. To our knowledge, this is the first paper to
demonstrate that the therapeutic capacity of hMSCs isolated from aging donors can be enhanced
through serial passaging on a custom synthetic material. The findings presented here offer insight for
designing clinically relevant materials for hMSC-based therapies.
2. Results
2.1. Experimental Design
The synthesis of the PEG-PCL polymer was based on ring opening polymerization of
ε-caprolactone onto methoxy-PEG (Figure 1A). X and Y refer to the mole percent fraction of PEG and
PCL, respectively. Based on prior work in our group [31], we utilized a 5% PEG–95% PCL copolymer
in which the PEG block was 2000 Da in size [32]. This polymer served as a favorable hMSC culture
substrate in that in vivo-like cell morphologies were adopted by the cells in addition to reinstatement
of an in vivo surface marker, STRO-1, and lowered ROS load compared to hMSCs cultured on TCPS.
For the current study, a spin coater was employed in order to create easily reproducible copolymer
films that the cells could grow on (Figure 1B). As illustrated, a Pyrex© Petri dish (or coverslip) was
placed in the spin coater with a small amount of copolymer solution added in the center. The rotation of
the block spread the solution evenly across the surface of the dish (or coverslip) yielding the copolymer
film in a culture-ready vessel, and additional spinning at a higher rate allowed for the volatile organic
solvent to evaporate, leaving a thin, uniform polymer film on the glass surface.
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Figure 1. Experimental overview. (A) The poly(ethylene glycol)-poly(ε-caprolactone) (PEG-PCL) 
copolymer was synthesized using methoxy-PEG and ring-opening polymerization of ε–caprolactone; 
(B) polymer films were generated by spin-coating copolymer solution onto coverslips or into Pyrex© 
petri dishes as shown in the illustration. First, a set volume of 1% w/v PEG-PCL solution was dropped 
onto coverglass or Pyrex© Petri dishes. The coverglass or dishes were placed into the spin coater and 
a spin program (green arrows) was applied to the substrates. The PEG-PCL solution was evenly 
spread out on the surface with the solvent evaporating in the process; (C) the timeline of experiments 
with respect to passage number of the donor human mesenchymal stem cells (hMSCs). Red indicates 
that passage numbers where imaging or functional tests were performed. 
For the longitudinal study, patient hMSCs were isolated from donors, expanded two passages 
on TCPS, and then subsequently cultured to passage 6 on either TCPS or PEG-PCL substrates (Figure 
1C). Upon initial collection of bone marrow aspirate, the bone marrow was passed through a 70 μm 
filter, cultured on Histoplaque, and the mononuclear cells were collected and subsequently plated on 
TCPS. The hMSCs were the only cells to adhere to TCPS dishes at passage 0. Non-adhesive cells 
obtained from the filtered bone marrow aspirate (e.g., hematopoietic stem cells) were removed by 
media aspiration and gentle media washes. The adhesive cells were grown to confluence before being 
evaluated for appropriate positive and negative MSC markers at passage 1 (refer to Balikov et al. 
[31]). Cells were frozen following a standard stem cell culture method utilizing 70% complete media, 
20% FBS (fetal bovine serum), and 10% DMSO (dimethyl sulfoxide) prior to serial passaging. As 
indicated in the Figure 1C, cells were passaged every 4 days, the time needed for hMSCs from all 
three donors to become confluent on TCPS. At day 4, cells were removed from either TCPS or PEG-
PCL and then re-plated onto a fresh culture substrate of the same material at the same cell seeding 
density of 10,000 cells/cm2. Four days of cell growth was chosen due to TCPS culture reaching nearly 
100% confluency at 96 h post-seeding at 10,000 cells/cm2. At passages 3 and 6, hMSCs were evaluated 
for functional capacity by evaluating cell morphology, intracellular ROS load, and osteogenic and 
adipogenic differentiation capacity. The total number of cells collected from PEG-PCL films were 
nearly double than that initially seeded, while the total number of cells collected from TCPS was 
nearly triple the amount originally seeded. 
2.2. Morphological Change of hMSCs on TCPS and PEG-PCL over Passages 
hMSCs from all donors showed markedly altered cellular morphology when passaged on TCPS 
or PEG-PCL (Figure 2). At passage 3, hMSCs grown on TCPS displayed a flattened, spread shape 
typical of this cell type. Most cells were oriented along a single major axis, and actin stress fiber 
Figure 1. Experimental overview. (A) The poly(ethylene glycol)-poly(ε-caprolactone) (PEG-PCL)
copolymer was synthesized using methoxy-PEG and ring-opening polymerization of ε–caprolactone;
(B) polymer films were generated by spin-coating copolymer solution onto coverslips or into Pyrex©
petri dishes as shown in the illustration. First, a set volu e of 1% w/v PEG-PCL solution was dropped
onto coverglass or Pyrex© Petri dishes. The coverglass or dishes were placed into the spin coater and a
spin program (green arrows) was applied to the substrates. The PEG-PCL solution was evenly spread
out on the surface with the solvent evaporating in the process; (C) the timeline of experiments with
respect to passage number of the donor human esenchymal stem cells (hMSCs). Red in icates that
passage numbers where imaging or functio al tests were performed.
For the longitudinal study, patient hMSCs were isolated from donors, expanded two passages on
TCPS, and then subsequently cultured to passage 6 on either TCPS or PEG-PCL substrates (Figure 1C).
Upon initial collection of bone marrow aspirate, the bone marrow was passed through a 70 µm
filter, cultured on Histoplaque, and the mononuclear cells were collected and subsequently plated
on TCPS. The hMSCs were the only cells to adhere to TCPS dishes at passage 0. Non-adhesive cells
obtained from the filtered bone marrow aspirate (e.g., hematopoietic stem cells) were removed by
media aspiration and gentle media washes. The adhesive cells were grown to confluence before being
evaluated for appropriate positive and negative MSC markers at passage 1 (refer to Balikov et al. [31]).
Cells were frozen following a standard stem cell culture method utilizing 70% complete media, 20%
FBS (fetal bovine serum), and 10% DMSO (dimethyl sulfoxide) prior to serial passaging. As indicated
in the Figure 1C, cells were passaged every 4 days, the time needed for hMSCs from all three donors
to become confluent on TCPS. At day 4, cells were removed from either TCPS or PEG-PCL and
then re-plated onto a fresh culture substrate of the same material at the same cell seeding density of
10,000 cells/cm2. Four days of cell growth was chosen due to TCPS culture reaching nearly 100%
confluency at 96 h post-seeding at 10,000 cells/cm2. At passages 3 and 6, hMSCs were evaluated
for functional capacity by evaluating cell morphology, intracellular ROS load, and osteogenic and
adipogenic differentiation capacity. The total number of cells collected from PEG-PCL films were
nearly double than that initially seeded, while the total number of cells collected from TCPS was nearly
triple the amount originally seeded.
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2.2. Morphological Change of hMSCs on TCPS and PEG-PCL over Passages
hMSCs from all donors showed markedly altered cellular morphology when passaged on TCPS
or PEG-PCL (Figure 2). At passage 3, hMSCs grown on TCPS displayed a flattened, spread shape
typical of this cell type. Most cells were oriented along a single major axis, and actin stress fiber
organization was clearly visible. However, when hMSCs were cultured on PEG-PCL, distinct cell
clusters, reminiscent of hanging drop aggregates, were formed. Cells within the aggregates were round
in morphology, with some cells exhibiting spindle-like extensions. Actin stress fibers were only present
on the few cells that had spindle-like extensions, while rounded cells within the cell aggregate had
minimal polarized actin fiber staining. At passage 6, TCPS hMSCs were highly aligned with strong
spindle morphology, forming a cell sheet. Actin stress fibers were still clearly demarcated, coupled
with the cells aligning along a major axis. With respect to PEG-PCL substrates, hMSCs continued to
form aggregate cell clusters, but both diameter and number of constituent cells increased by visual
inspection. Furthermore, the diversity in spheroid morphology can be seen among the donors, in
which donor 2 maintained a tight, enlarged spheroid of cells, donor 1 had more cellular spindle
projections anchoring to the copolymer surface, and donor 3 contained a spheroid with a broad based
of spindle-shaped hMSCs along the copolymer surface like a cell-feeder layer. Of note, passage 6 was
not exceeded in this study due to the spheroids becoming so large that they no longer adhered to the
surface of the PEG-PCL, thereby rendering the beneficial aspects of the copolymer substrate ineffective.
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2.3. ROS Load 
All donors displayed decreased levels of detected intracellular ROS when grown on the PEG-
PCL compared to TCPS (Figure 3). Passage 3 fluorescent signal was decreased by ~1 order of 
magnitude, and this effect was maintained at passage 6. TCPS curves (blue) had a tight population 
distribution while PEG-PCL (green) was more heterogenous, as seen by the increased peak width. 
This could be due to differences in the cells closer to the material interface (likely with higher ROS) 
compared to the cells within in the cell aggregate (lower ROS). 
Figure 2. Morphological changes occur over serially passaging human mesenchymal stem cells on
their respective substrates. Cells were stained with AlexaFluor-488-conjugated phalloidin (green) and
Hoechst nuclear counterstain (blue). Scale bar = 100 µm.
2.3. ROS Load
All donors displayed decreased levels of detected intracellular ROS when grown on the PEG-PCL
compared to TCPS (Figure 3). Passage 3 fluorescent signal was decreased by ~1 order of magnitude,
and this effect was maintained at passage 6. TCPS curves (blue) had a tight population distribution
while PEG-PCL (green) was more heterogenous, as seen by the increased peak width. This could be
due to differences in the cells closer to the material interface (likely with higher ROS) compared to the
cells within in the cell aggregate (lower ROS).
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Figure 3. PEG-PCL copolymers reduce i t l r ROS load of donor cells at both passages. Human
mesenchymal stem cells (hMSCs) were inc ate ith DCFDA, and FITC intensity correlated with
active ROS species. The graphs shown are representative results from n = 3 independent experimental
replicates. Blue is TCPS and green is PEG-PCL. All donors for both passages had decreased ROS loads
for hMSCs grown on PEG-PCL compared to TCPS.
2.4. Differentiation Capacity
The degree of osteogenic differentiation, as evaluated by image-based quantification of Alizarin
Red stai , w s maintained wh n hMSCs were serially p ssaged on PEG-PCL (Figure 4). Different
staining patterns w e observed across all do ors at pas age 3, with enhanced mineralization for donor 2.
However, at passage 6, staining i tens ty was markedly decreas d on TCPS, with minimal staining for
donor 2. Adipoge ic differentiati n had mixed results across all donors (Figure 5). Staining patterns of
Oil Red O for TCPS and PEG-PCL did not show unique patterning or oil droplet shape, nor were there
statistically significant differences in staining intensity between the substrates at either passage.Int. J. Mo . Sci. 2018, 19, x FOR PEER REVIEW  7 of 14 
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of aggregates with a small interfacing cell layer on the material that act like a “feeder layer” has been 
Figure 5. Adipogenic differentiation of h S . ere stained with Oil Red O after one month
of adipogenic differ ntiation. Oil Red st i t pear di ferent across all donors for both
passages, and het rogeneity of dr l t si can be s en in the images. Mean i tensity of the stain
is lotte for all onors for each s bstrate ith n = 3 independent experimental replicates, and no
significant differences between TCPS and PEG-PCL ere reported. Scale bar = 100 µm.
3. Discussion
Longitudinal, serial passage of hMSCs for regenerative medicine and tissue engineering-based
therapies is undoubtedly a prerequisite that is critical to clinical success. Regardless of allogenic or
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autologous donor cells, ensuring that a sizable stem cell mass is prepared for host injection enables
the greatest chance for engraftment. However, in the process of expanding stem cells, phenotype
characteristics associated with senescence could inhibit success rates of future stem cell therapies and
potentially raise the risk of harming patients. Therefore, different culture strategies ranging from
pro-aggregate culture vessels to minimally-disrupted monolayer substrates have been explored for
culturing hMSCs ex vivo [15,20,26–28]. Here, we sought to employ a copolymer composed of PEG-PCL
that has been shown in previous work to regulate hMSC function through nanoscale interactions as
a culture platform to expand healthy cells from aging donors. We have demonstrated that hMSCs
cultured on the PEG-PCL material maintain osteogenic capacity and a lower ROS level than those
cultured on TCPS.
Prior work in our lab discovered that carefully tuning of PEG-PCL copolymer composition
manipulated the homeostasis of hMSCs towards a more potent and potentially therapeutic
phenotype [31]. Of note, this previous work also demonstrated that cells on PEG-PCL materials
exhibited a significantly reduced proliferation rate compared to those grown on TCPS, although
cells on both materials were proliferative (approximately 40% on TCPS versus 10–20% on PEG-PCL).
Similar to the aforementioned study, cells on the copolymer were into a forced aggregation state, but
as the passage number progressed, the size of these aggregates increased (Figure 2). The formation of
aggregates with a small interfacing cell layer on the material that act like a “feeder layer” has been seen
in vivo in the bone marrow [33–35]. Additionally, speculation of hMSCs being related to pericytes,
which is still under debate in the field, demonstrates the same balance of cell-cell (pericyte-endothelial
cell) and cell-matrix interaction (pericyte-surrounding ECM), and the PEG-PCL appears to cause the
hMSCs to behave as if they were in a bone marrow or capillary-like environment [36]. A separate
study conducted by our research group observed that the hMSCs culture on PEG-PCL formed a thin
monolayer interface with the copolymer film followed by a significant accumulation of cells that
created a spheroid cell mass [32]. While these structures were only studied for one passage on the
copolymer film, the change in hMSC phenotype over continuous serially passaging on the copolymer
films could influence the preference of the hMSCs to engage in stronger and more numerous cell-cell
contacts, hence resulting in larger cell aggregates by passage 6. Of additional note, the qualitative
differences in spheroid morphologies observed are likely due to inherent differences among the donors,
as has been reported in the literature [37,38], although no measurable parameter can be identified as
causing these morphological disparities.
Because the functional capacity of hMSCs has direct effects on their clinical usefulness, the first
functional test evaluated was ROS load in the hMSCs. It is well known that general cell health decreases
as ROS increases in the cell, thereby increasing the likelihood of cancerous or apoptotic-inducing
changes occurring [39]. ROS loads for hMSCs cultured on TCPS for both passages were higher than
those cultured on PEG-PCL (Figure 3). This aligned with previous literature reporting stem cell niches
(exhaustively reviewed by Zhou, Shao, and Spitz [40]). A small, healthy fraction of stem cells that
replenish the stem cell population has naturally low amounts of ROS. This is also logical given that
ROS can also damage DNA, increasing risk of abnormal cell behavior. Because hMSCs cultured on
PEG-PCL maintained a similar level of ROS through passage 6, our substrate appears to keep these
hMSCs in a pro-stem cell state and correlates with the growing size of the aggregates (Figure 2).
This explanation is further supported by a study by Zhang et al. that showed spheroid aggregates
of gingiva-derived hMSCs expressed SOD2 (an antioxidant protein) throughout the aggregate [41].
As seen in Figure 2, the ROS curves for cells on PEG-PCL are wider than those for TCPS, indicating
a greater distribution in the ROS load for cells on the copolymer substrate, which could be due to
their location within the cell aggregates. That is, cells in direct contact with the surface might have a
different ROS state than those within the middle of the cell aggregate.
hMSCs used for future tissue engineering therapies will likely be differentiated into other cell
types for healing damaged tissues. Hence, differentiation assays were conducted for osteogenesis
and adipogenesis (Figures 4 and 5). In the original publication defining the bone marrow stromal
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population, researchers confirmed that the stromal cells were multipotent and able to differentiate
into multiple mesenchymal stem types including bone, cartilage, and fat [42]. hMSCs have also
been differentiated into neurons [43] and cardiac cells [44], but for this study osteogenesis and
adipogenesis were employed in order to compared to long-established literature. Osteogenic potential
was maintained for hMSCs cultured on PEG-PCL, while the ability for successful mineralization
was abrogated by passage 6 for TCPS. Loss of osteogenic potential is known to occur due to
senescence-associated changes [45–47], and that donor source does not influence the degree of
differentiation but rather the phenotype of the hMSCs prior to differentiation induction [48], thus
validating that the pro-stemness phenotype was maintained on PEG-PCL. Of equal note, it has been
shown that spheroid morphologies adopted in hMSC culture improve the degree of osteogenesis [49],
even going so far as to determine that enhanced epigenetic changes promoting pro-stem cell
transcription factors prior to induction drove increased activity in pro-osteogenic proteins like alkaline
phosphatase [50]. However, no significant changes were seen in adipogenic differentiation. This
result has been reported by Cheng et al. in which bone-marrow derived hMSCs did not exhibit
increased efficiency in adipogenic differentiation following culture on chitosan films, while osteogenic
differentiation was markedly enhanced along with increased RUNX2 expression [51]. The results
could also be due to the age of the donors utilized in this study, thereby reducing their differentiation
capacity [11].
4. Materials and Methods
4.1. Polymer Substrate Preparation
5% PEG (Mw = 2000 Da)—95% PCL (PEG-PCL) was synthesized using methods previously
described [52]. Briefly, PCL was extended from the free end of methoxy-PEG by ring-opening
polymerization of distilled ε-caprolactone at 120 ◦C for 4 h and then precipitated in ice-cold diethyl
ether. The copolymer was then desiccated to remove excess diethyl ether, thereby leaving the final
copolymer product behind. Spin-coated polymer films were prepared with a commercial spin-coater
(Laurell Technologies, North Wales, PA, USA). 15 mm circular glass cover slips (Fisher Scientific,
Hampton, NH, USA) were first cleaned with 100% ethanol (Sigma Aldrich, St. Louis, MO, USA),
rinsed with dH2O, and heated to 80 ◦C for ~20 min to dry. A 1% weight/volume (w/v) solution of
the copolymer in tetrahydrofuran (THF, Sigma Aldrich, St. Louis, MO, USA) was spun for 30 s at
3000 RPM atop the clean glass cover slip. For preparation of “large-scale” Petri dish polymer films,
Pyrex Petri dishes (Corning Inc., Corning, NY, USA) were cleaned as described above, and 1 mL of a
1% w/v solution of polymer in THF was spun for 2 min at 1500 RPM to coat the surface. All samples
were then exposed to constant vacuum for ≥30 min to remove excess solvent and kept in a desiccator
until use. Coverslips and dishes were UV sterilized for 60 min before use for cell culture.
4.2. Cell Culture
hMSCs were acquired from three patients at Vanderbilt University Medical Center in cooperation
with Dr. Pampee P. Young, according to previously published methods [53]. To briefly summarize,
bone marrow isolates were diluted in HBSS and passed through a 70 µm filter, which was subsequently
plated onto Histopaque (Sigma Aldrich). The non-adherent cells were washed away and replated on
TCPS in complete media. Once the cells were confluent, they were passaged and a small fraction was
saved for MSC phenotyping using a Human MSC Phenotyping Kit from Miltenyl Biotec (Auburn,
CA, USA). Flow cytometry was performed with this kit to evaluate expression of CD14, CD20, CD34,
CD45, CD73, CD90, and CD105. All donors were CD14/20/34/45 negative and CD73/90/105 positive
at greater than 99% of the sample population as described in our previous report by Balikov et al. [31].
All patients provided informed consent for use of their bone marrow aspirates for research purposes.
Processing and handling of the cells were carried out in accordance to relevant guidelines and
regulations established by both Vanderbilt University and the National Institutes of Health, and
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experimental protocols were reviewed and approved by the Vanderbilt Institutional Review Board.
All patients were male and over the age of 65 with no known blood disorders or cancer diagnosis
at the time of bone marrow harvest. hMSCs were maintained in complete media (CM) composed of
alpha-minimum essential media with nucleosides (αMEM, Life Technologies, Carlsbad, CA, USA)
with 16.7% fetal bovine serum (Life Technologies), 1% penicillin/streptomycin (Life Technologies), and
4 µg/mL plasmocin (InvivoGen, San Diego, CA, USA). Cells were kept in a humidified incubator at
37 ◦C and 5% CO2, and media was replaced twice each week. For all experiments, hMSCs were seeded
at a density of 10,000 viable cells/cm2, as determined by exclusion of Trypan blue, and cultured for
four days before passaging.
4.3. Immunocytochemistry
hMSCs were fixed with 4% paraformaldehyde (PFA, Sigma Aldrich) for 15 min, permeabilized
with 0.3% Triton-X (Sigma Aldrich) for 15 min when probing intracellular targets, and blocked with
10% goat serum (Sigma Aldrich) for >2 h, all at room temperature. Cells were incubated with
Alexa488-phallodin (1:40 v/v in Phosphate-Buffered Saline, Life Technologies) for 10 min followed by
counterstaining with Hoechst (Sigma Aldrich, 2 µg/mL) for 20 min at room temperature. Imaging
was performed with a Zeiss LSM 710 confocal microscope (Carl Zeiss, Oberkochen, Germany), and
images were processed with ImageJ (National Institutes of Health, Bethesda, MD, USA).
4.4. Measuring Levels of Intracellular Reactive Oxygen Species (ROS)
hMSCs were incubated with 10 µM 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein
diacetate acetyl ester (DCFDA) (Life Technologies) in serum-free DMEM for 30 min following the
manufacturer’s instructions. Cells were trypsinized and run on a BD LSR Fortessa (BD Biosciences,
Franklin Lakes, NJ, USA) with the appropriate unstained control. n = 3 biological replicates were
conducted per substrate condition. Data were analyzed by FlowJo software (Tree Star Inc., Ashland,
OR, USA).
4.5. Differentiation Assay
hMSCs were grown on TCPS or PEG-PCL at their indicated passage for 4 days before being
trypsinized and moved to 24-well TCPS plates. Differentiation assays were performed based on
pre-established protocols [54,55]. Adipogenic media using AMEM contained 16.7% FBS, 1% penicillin/
streptomycin, 4 µg/mL plasmocin, 0.1 µM dexamethasone, 0.45 mM 3-isobutyl-1-methylxantine,
0.2 mM indomethacin 1 µg/mL insulin, and 1 µM rosiglitazone. Osteogenic media using AMEM
contained 16.7% FBS, 1% P/S, 4 µg/mL plasmocin, 10 nM dexamethasone, 5 mM β-glycerophosphate,
and 50 µg/mL ascorbate-2-phosphate. All specialized differentiation media reagents were purchased
from Sigma-Aldrich. Cells were cultured under induction media for one month and then fixed with
4% PFA. Cells were stained with Oil Red O (ORO) and Alizarin Red S (ARS) for adipogenic and
osteogenic staining, respectively. Images were taken with a Nikon Ti inverted microscope (Nikon
Instruments Inc., Melville, NY, USA) and processed with ImageJ. Stain quantification was performed
on n = 3 independent experimental replicates. Images were first converted to a RGB stack followed
by setting a threshold range in the green channel to account for variation in background light from
brightfield imaging. The images were inverted resulting in a new grayscale image, and mean intensity
was measured.
4.6. Statistical Analysis for ROS and Differentiation Assays
Comparisons between substrates for differentiation assays were performed with a Student’s
unpaired t-test. In all cases, p < 0.05 is considered statistically significant. Mean ± standard deviation
is reported, unless otherwise noted.
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5. Conclusions
In this study, we explored the ramifications of serially passaging human bone marrow-derived
hMSCs from aged patient donors on a novel PEG-PCL copolymer film to maintain functional capacity
and stem cell phenotype for future applications in tissue engineering and regenerative medicine.
hMSCs grown on the films illustrated morphologies representative of hMSCs found in vivo and
maintained low ROS loads that if unchecked are known to be associated with the progression of
senescence-associated changes. Finally, the maintenance of differentiation capacity of PEG-PCL hMSCs
demonstrated relevance of using our alternative copolymer film to maintain stem cell functionality for
downstream hMSC adoption of target tissue cell types.
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